This is a working overview of lipogenesis, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-11. Anything still debated is marked as such rather than presented as settled.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
In a broad academic audience, the concept of the evolution of the genetic code from its original ambiguous form to a well-defined ("frozen") code with the repertoire of 20 (+2) canonical amino acids is widely accepted. However, there are different opinions, concepts, approaches and ideas regarding how to best reproduce this process experimentally. Even models are proposed that predict "entry points" for synthetic amino acid invasion of the genetic code. Since 2001, 40 non-natural amino acids have been added into proteins by creating a unique codon (recoding) and a corresponding transfer-RNA:aminoacyl – tRNA-synthetase pair to encode it with diverse physicochemical and biological properties in order to be used as a tool to exploring protein structure and function or to create novel or enhanced proteins. H. Murakami and M. Sisido extended some codons to have four and five bases. Steven A. Benner constructed a functional 65th (in vivo) codon. In 2015 N. Budisa, D. Söll and co-workers reported the full substitution of all 20,899 tryptophan residues (UGG codons) with unnatural thienopyrrole-alanine in the genetic code of the bacterium E. coli. In 2016 the first stable semisynthetic organism was created. It was a (single cell) bacterium with two synthetic bases (called X and Y). The bases survived cell division. In 2017, researchers in South Korea reported that they had engineered a mouse with an extended genetic code that can produce proteins with unnatural amino acids. In May 2019, researchers reported the creation of a new "Syn61" strain of the E. coli bacteria.
Fine structure of taste buds in the barbel of the catfish, Ictalurus punctatus. Cell Tissue Res 169, 395–403. Hawkins, M. B. (n.d.). The development and evolutionary origin of barbels in the channel catfish Ictalurus punctatus (Siluriformes: Ictaluridae). 48. Joyce, E. C. and Chapman, G. B. (1978). Fine structure of the nasal barbel of the channel catfish, Ictalurus punctatus. Journal of Morphology 158, 109–153. Kapoor, B. G., Evans, H. E., & Pevzner, E. A. (1976). The Gustatory System in Fish. In Advances in Marine Biology (Vol. 13, pp. 53–108). Elsevier. https://doi.org/10.1016/S0065-2881(08)60280-1 LeClair, E.E. and Topczewski, J. (2009). Methods for the study of the zebrafish maxillary barbel. J Vis Exp, http://www.jove.com/video/1558/methods-for-the-study-of-the-zebrafish-maxillary-barbel?id=1558, doi:10.3791/1558. LeClair, E.E. and Topczewski, J. (2010). Development and regeneration of the zebrafish maxillary barbel: a novel study system for vertebrate tissue growth and repair. PLoS One 5, e8737. McCormick, M. I. (1993). Development and changes at settlement in the barbel structure of the reef fish, Upeneus tragula (Mullidae). Environmental Biology of Fishes, 37(3), 269–282. https://doi.org/10.1007/BF0000463 Ogawa, K., Marui, T. and Caprio, J. (1997). Bimodal (taste/tactile) fibers innervate the maxillary barbel in the channel catfish. Chem Senses 22, 477–82. von der Emde, G., Mogdans, J., & Kapoor, B. G. (Eds.). (2004). The Senses of Fish. Springer Netherlands.
== Industry and Research Community == Commercial products and companies based on aptamers include the drug Macugen (pegaptanib) and the clinical diagnostic company SomaLogic. The International Society on Aptamers (INSOAP), a professional society for the aptamer research community, publishes a journal devoted to the topic, Aptamers. Apta-index is a current database cataloging and simplifying the ordering process for over 700 aptamers.
The ability to purify DNA from a sample is important for many modern biotechnology processes. However, samples often contain nucleases that degrade the target DNA before it can be purified. It has been shown that DNA fragments will partition into the light phase of a polymer–salt separation system. If ligands known to bind and deactivate nucleases are incorporated into the polymer phase, the nucleases will then partition into the heavy phase and be deactivated. Thus, this polymer–salt system is a useful tool for purifying DNA from a sample while simultaneously protecting it from nucleases.
=== Financial operations === It is difficult to trace the financial movements of the CJNG given its multifaceted and illegal nature, but some estimate their assets to be worth over $20 billion. The main source of revenue for the cartel is the trade of illegal drugs, which is extremely profitable with markets in the United States and the EU. Money laundering through real estate investments, front businesses, cryptocurrency, and offshore financial institutes help the CJNG to disguise and distribute large sums. Key to the cartel's large revenue gains is its rapid geographic expansion; the CJNG has captured key ports of entry along the Gulf and the Pacific since its rise in 2009, increasing its ability to extract key elements of the illegal drug supply chain. Although the CJNG generates significant revenues from narco-trafficking, the takeover of non-drug related industries, which often capitalize on the expertise of local gangs who have been absorbed by the CJNG, help the cartel to create more immediate revenues and establish regional control. A variety of peripheral operations, such as extortion of tortilla, avocado, lime, and chicken industries, as well as fuel theft and counterfeit time-share dealings, help the CJNG to accumulate revenue to fund the trafficking of illegal drugs like fentanyl, cocaine, and methamphetamine into the United States. The cartel relies on the extortion of agricultural farms, recently profiting greatly off of Mexico's 'green gold', avocados.
Sources: en.wikipedia.org
== Career == Cooks became an assistant professor at Kansas State University from 1968 to 1971. In 1971, he took a position at Purdue University. He became a professor of chemistry in 1980 and was appointed the Henry Bohn Hass Distinguished Professor in 1990. Cooks was co-editor of the Annual Review of Analytical Chemistry from 2013 to 2017.
=== Systems Pharmacology === Systems Pharmacology models integrate pharmacokinetics, pharmacodynamics, and systems biology to provide a comprehensive understanding of drug effects. By considering the intricate interplay between drugs, biological systems, and disease pathways, these models contribute to a holistic approach to drug development and personalized medicine.
== Athletic tracking and self-tracking uses == Hemoglobin can be tracked noninvasively, to build an individual data set tracking the hemoconcentration and hemodilution effects of daily activities for better understanding of sports performance and training. Athletes are often concerned about endurance and intensity of exercise. The sensor uses light-emitting diodes that emit red and infrared light through the tissue to a light detector, which then sends a signal to a processor to calculate the absorption of light by the hemoglobin protein. This sensor is similar to a pulse oximeter, which consists of a small sensing device that clips to the finger.
Patients with active internal bleeding Patients with a recent (within 3 months) hemorrhagic stroke Patients with a recent (within 2 months) intracranial/intraspinal surgery/severe head trauma Trauma patients with an increased risk of life-threatening bleeding Patients with an epidural catheter Patients with a known or suspected intracranial neoplasm or mass lesion Patients with known hypersensitivity to drotrecogin or any component
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.